Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature

Drooger, Jan C.; Hooning, Maartje J.; Seynaeve, Caroline; Baaijens, Margreet H.A.; Obdeijn, Inge Marie; Sleijfer, Stefan; Jager, Agnes

doi:10.1016/j.ctrv.2014.12.002

Cited by 49 publications

(45 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following mastectomy, adjuvant radiation is used more often in AYAs compared with older women . BRCA mutation carriers may have a higher incidence of radiation‐induced malignancies …”

Section: Treatment and Managementmentioning

confidence: 99%

Breast cancer in adolescents and young adults

Johnson

Anders

Litton

et al. 2018

Pediatric Blood & Cancer

161

117

View full text Add to dashboard Cite

Breast cancer is the most common cancer of adolescents and young adult (AYA) women aged 15 to 39 years, accounting for 5.6% of all invasive breast cancer in women. In comparison with older women, AYAs are more likely to have familial cancer predisposition genes, larger breast tumors, unfavorable biological characteristics, distant metastatic disease at diagnosis, and adverse outcome. Endocrine therapy and some chemotherapy recommendations differ between young and older women. AYAs require coordinated multidisciplinary care, treatment regimens that minimize late effects such as premature menopause and osteoporosis, and proactive management of psychological and sexual health during and after cancer treatment.

show abstract

“…Following mastectomy, adjuvant radiation is used more often in AYAs compared with older women . BRCA mutation carriers may have a higher incidence of radiation‐induced malignancies …”

Section: Treatment and Managementmentioning

confidence: 99%

Breast cancer in adolescents and young adults

Johnson

Anders

Litton

et al. 2018

Pediatric Blood & Cancer

161

117

View full text Add to dashboard Cite

show abstract

“…A large number of risk factors for breast cancer have now been identified. These include: Geographic variations; race and ethnicity (2,3); prolonged exposure to exogenous estrogens post-menopausally (including hormone replacement therapy used in the prevention of osteoporosis) (4–7); obesity (due to estrogens produced by the adipose tissue) (8–10); alcohol abuse (11); genetic inheritance (mutations in breast cancer 1 and 2) (12–14); lack of physical activity (15); ionizing radiation to the chest (depending on radiation dose, age and time following exposure) (16–19); and early age at menarche or late age of pregnancy and menopause (20). …”

Section: Introductionmentioning

confidence: 99%

Age-associated prognostic and predictive biomarkers in patients with breast cancer

et al. 2017

View full text Add to dashboard Cite

To date, no comprehensive prognostic or predictive marker profiling analysis has been performed in association with the age of patients with breast cancer. In the present study, 632 breast cancer tissue samples were analyzed for expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), B-cell lymphoma (Bcl)-2 protein, HER2 gene amplification, proliferation [as evaluated by proliferating cell nuclear antigen (PCNA) and Ki-67 index], tumor grade, histological type and molecular subtype. The data revealed correlations with the age of patients. A statistically significant positive correlation was identified between patient age and expression of ER (P<0.0001). There was no significant association between patient age and PR, HER2 protein expression, HER2 gene amplification or PCNA. A significant negative correlation between age and Ki-67 expression (P<0.0001) as well as grade of tumor (P=0.007) was identified. The spectrum of molecular subtypes differed according to age (P=0.0003). The highest incidence of aggressive triple-negative and HER2-positive breast cancer was present in patients aged between 20 and 39 years. Luminal A subtype was the most frequent cancer subtype in patients from age 40 onwards, where proliferation activity declined with age and expression of hormone receptors increased along with Bcl-2 expression. Aggressive forms of breast cancer were more common in younger patients. Prognostic and predictive markers have a complex age-specific distribution. The findings of less aggressive luminal A and B subtypes in older patients, and the positive correlation with ER, PR and Bcl-2 expression reveal the potential efficacy of Bcl-2 as a marker of hormone responsiveness in these patients.

show abstract

“…Nevertheless, Moon et al [125] observed increased incidence of hypersensitivity reactions in BRCA1/2-mutated ovarian cancer patients receiving carboplatin and olaparib. There is also a discussion whether therapeutic radiation is associated with increased risk of induced cancers in BRCA1/2 heterozygotes [126, 127]. …”

Section: Introductionmentioning

confidence: 99%

Cytotoxic and targeted therapy for hereditary cancers

Iyevleva

Imyanitov

2016

Hered Cancer Clin Pract

View full text Add to dashboard Cite

There is a number of drugs demonstrating specific activity towards hereditary cancers. For example, tumors in BRCA1/2 mutation carriers usually arise via somatic inactivation of the remaining BRCA allele, which makes them particularly sensitive to platinum-based drugs, PARP inhibitors (PARPi), mitomycin C, liposomal doxorubicin, etc. There are several molecular assays for BRCA-ness, which permit to reveal BRCA-like phenocopies among sporadic tumors and thus extend clinical indications for the use of BRCA-specific therapies. Retrospective data on high-dose chemotherapy deserve consideration given some unexpected instances of cure from metastatic disease among BRCA1/2-mutated patients. Hereditary non-polyposis colorectal cancer (HNPCC) is characterized by high-level microsatellite instability (MSI-H), increased antigenicity and elevated expression of immunosuppressive molecules. Recent clinical trial demonstrated tumor responses in HNPCC patients treated by the immune checkpoint inhibitor pembrolizumab. There are successful clinical trials on the use of novel targeted agents for the treatment or rare cancer syndromes, e.g. RET inhibitors for hereditary medullary thyroid cancer, mTOR inhibitors for tumors arising in patients with tuberous sclerosis (TSC), and SMO inhibitors for basal-cell nevus syndrome. Germ-line mutation tests will be increasingly used in the future for the choice of the optimal therapy, therefore turnaround time for these laboratory procedures needs to be significantly reduced to ensure proper treatment planning.

show abstract

Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature

Cited by 49 publications

References 63 publications

Breast cancer in adolescents and young adults

Breast cancer in adolescents and young adults

Age-associated prognostic and predictive biomarkers in patients with breast cancer

Cytotoxic and targeted therapy for hereditary cancers

Contact Info

Product

Resources

About